img

News Topical, Digital Desk : Q2 Results: Pharma company Aarti Drugs and non-banking finance company Cholamandalam Investment & Finance (Chola Fin) have announced their results for the second quarter (Q2 FY26) of FY 2025-26. Both companies have improved their performance on a year-on-year (YoY) basis.

Aarti Drugs Ltd, a leading pharmaceutical company, has performed well in the second quarter. The company's consolidated net profit increased from ₹35 crore to ₹45 crore, a growth of approximately 28%.

Consolidated revenue also increased from ₹598 crore to ₹653 crore, representing an increase of approximately 9% in earnings. The company's EBITDA increased from ₹67 crore to ₹84 crore, while the EBITDA margin increased from 11.2% to 12.9%. The company has strengthened its profitability due to better operational efficiency and improved product mix. 

Cholamandalam Investment Q2 Results Chola Finance has reported stable performance in the second quarter of FY 2025-26. The company's consolidated profit increased from ₹526 crore to ₹550 crore, a 4.5% increase. Net interest income (NII), the main source of revenue from the loan business, increased from ₹2,994 crore to ₹3,683 crore, a nearly 23% increase. This growth was driven by strong disbursements, improved asset quality, and a steadily expanding retail loan portfolio.
 


Read More: FIIs Data: Strong return of foreign investors in Indian market, bought shares worth so many billions in the month of October

--Advertisement--

Aarti Drugs Q2 results Aarti Drugs FY26 earnings Aarti Drugs profit growth Aarti Drugs EBITDA margin Aarti Drugs revenue rise Cholamandalam Finance Q2 results Chola Fin earnings report Chola Finance NII growth Chola Finance profit FY26 Q2 results India 2025 pharma sector Q2 performance NBFC Q2 earnings Aarti Drugs and Chola Fin quarterly results